Betaxolol: a new long-acting beta 1-selective adrenergic blocker.
Betaxolol (Searle, Skokie, Illinois) is a new beta 1-selective adrenergic blocker with no partial agonist action and minimal membrane stabilizing activity. Its pharmacokinetic profile is characterized by a long serum half-life and excellent oral bioavailability, with little first-pass metabolism. The mean 16-hour half-life of betaxolol has been shown to provide full 24-hour control of blood pressure and heart rate. Betaxolol has been proven to be a safe and effective antihypertensive agent, and was recently approved for clinical use in the United States for this indication.
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.
W H
WH
Frishman
D
D
Tepper
E J
EJ
Lazar
D
D
Behrman
D000328:Adult; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000378:metabolism; D015784:Betaxolol / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000503:physiopathology; D008297:Male; D012307:Risk Factors; D013997:Time Factors
D015784:Betaxolol